BioSpace News Archive

ASMS 2021 -- Thermo Fisher Scientific, the world leader in serving science, today announced its acquisition of Belgium -based PharmaFluidics, the developer of the μPAC range of micro-chip-based chromatography columns.

Thirty-eight abstracts underscore AbbVie’s commitment to advancing its portfolio of medicines to help more people living with rheumatic diseases

Perspectum and HepQuant are proud to announce a strategic business partnership to provide seamless delivery of HepQuant’s liver function assessment technology via Perspectum’s Contract Research Organization (CRO) services.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that The Lancet has published four-year data highlighting the safety and efficacy of maralixibat in patients with Alagille syndrome (ALGS), a rare liver disease affecting one in 30,000 children.

Anika Therapeutics, Inc., a global joint preservation company focused on early intervention orthopedics, announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021.

IceCure Medical Ltd. announced that a peer reviewed article titled, “VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in Japan,” was published in the Journal of Cancer Therapy by lead author Dr. Hisanori Kawamoto, MD, PhD. from the Department of Breast Surgery Breast and Imaging Center, St. Marianna University School of Medicine, Japan.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that its license partner, China Oncology Focus Limited (COF), an affiliate of Lee’s Pharmaceutical Holdings Limited (Lee’s Pharma, HKEX: 950) has submitted a NDA (new drug application) for the anti-PD-L1 antibody, socazolimab, licensed from Sorrento to COF for the greater China territory to treat recurrent or metastatic cervical cancer.

Lab Genomics Announces MolDX® Coverage for Follow It® Circulating Tumor DNA Assay in Partnership with Canexia Health

ABK Biomedical, Inc. announced the approval and initiation of a First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device, in collaboration with Auckland Hospital Research Unit, New Zealand.

Rheos Medicines today announced new preclinical data showing the potential for MALT1 inhibitors for the treatment of autoimmune and inflammatory diseases